Stock BMY BRISTOL-MYERS SQUIBB COMPANY
Add to a list
To use this feature you must be a member
Log inSign up

Consensus Bristol-Myers Squibb Company

Equities

BMY

US1101221083

Market Closed - Nyse
Other stock markets
 04:00:02 2024-04-26 pm EDT 		5-day change 1st Jan Change
44.85 USD +0.34% Intraday chart for Bristol-Myers Squibb Company -8.34% -12.59%
Apr. 26 S&P 500 Q1 earnings estimated growth improves; stocks up for week RE
Apr. 26 Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT

Evolution of the average Target Price on Bristol-Myers Squibb Company

Price target over the last 5 years

History of analyst recommendation changes

23f55ef2942ba3f580634c0ffed8b33.fiKIqdQTBcaUv7ClaAkmckVXUAXTFqxmrr_-0hz10Cc.Exve6L9WQKDs_NWWBENjQHIDFHDicecHl8myn12llBMqZ_zd7GE9vMby0w~10d35372b9424f1f5deb6c09db618c10

Analyst Recommendations on Bristol-Myers Squibb Company

Leerink Partners Cuts Price Target on Bristol-Myers Squibb to $47 From $51 MT
UBS Cuts Bristol-Myers Squibb Price Target to $47 From $52, Maintains Neutral Rating MT
Barclays Adjusts Price Target on Bristol-Myers Squibb to $43 From $51 MT
JPMorgan Adjusts Bristol-Myers Squibb's Price Target to $60 From $65 MT
Morgan Stanley Adjusts Price Target on Bristol-Myers Squibb Company to $37 From $40 MT
Truist Cuts Price Target on Bristol-Myers Squibb to $64 From $68, Keeps Buy Rating MT
BMO Capital Adjusts Price Target on Bristol-Myers Squibb Company to $48 From $55 MT
Jefferies Adjusts Bristol-Myers Squibb Price Target to $54 From $56, Keeps Hold Rating MT
Cantor Fitzgerald Adjusts Price Target on Bristol-Myers Squibb to $45 From $52, Maintains Neutral Rating MT
Cantor Fitzgerald Adjusts Bristol-Myers Squibb's Price Target to $52 From $55, Maintains Neutral Rating MT
Wells Fargo Adjusts Bristol-Myers Squibb's Price Target to $52 From $51, Keeps Equalweight Rating MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb Company to $55 From $57, Outperform Rating Kept MT
Wolfe Research Adjusts Price Target on Bristol-Myers Squibb to $55 From $57, Maintains Outperform Rating MT
Jefferies Cuts Bristol-Myers Squibb's Price Target to $56 From $58 MT
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $40 From $41, Keeps Underweight Rating MT
Societe Generale Downgrades Bristol-Myers Squibb to Hold From Buy, Cuts Price Target to $51 From $85 MT
Wells Fargo Adjusts Price Target on Bristol-Myers Squibb to $51 From $58, Maintains Equalweight Rating MT
Redburn Downgrades Bristol-Myers Squibb to Neutral From Buy, Adjusts Price Target to $54 From $77 MT
That's good enough for investors Our Logo
ANALYST RECOMMENDATIONS : Chevron, McDonald's, Palantir, Sainsbury, Tesla... Our Logo
Morgan Stanley Trims Price Target on Bristol-Myers Squibb to $41 From $42, Incorporates Mirati Transaction Into Model; Underweight Kept MT
UBS Cuts Bristol-Myers Squibb Price Target to $52 From $57, Maintains Neutral Rating MT
Berenberg: M&A Dealmaking in Pharmaceutical Sector to Further Accelerate in 2024 MT
BofA Securities Downgrades Bristol-Myers Squibb to Neutral From Buy, Price Target is $60 MT
Morgan Stanley Cuts Price Target on Bristol-Myers Squibb to $42 From $50, Keeps Underweight Rating MT
More recommendations

Analysts' Consensus

Sell
Consensus
Buy
Mean consensus
HOLD
Number of Analysts
27
Last Close Price
44.85 USD
Average target price
54.02 USD
Spread / Average Target
+20.45%
High Price Target
75 USD
Spread / Highest target
+67.22%
Low Price Target
37 USD
Spread / Lowest Target
-17.50%

Consensus detail

Consensus revision (last 18 months)

Analysts covering Bristol-Myers Squibb Company

Leerink Partners
UBS
Barclays
JPMorgan Chase
Morgan Stanley
Truist Securities
BMO Capital
Jefferies & Co.
Cantor Fitzgerald
Wells Fargo Securities
Wolfe Research
Societe Generale
Redburn
BofA Securities
Deutsche Bank Securities
Daiwa Securities
Berenberg Bank
Goldman Sachs
William Blair & Co.
HSBC
TD Cowen
Credit Suisse
Atlantic Equities
Guggenheim
Raymond James
Citigroup
Argus

Ratings for Bristol-Myers Squibb Company

Trading Rating
Investor Rating
ESG Refinitiv
B
More Ratings

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar
  1. Stock Market
  2. Equities
  3. BMY Stock
  4. Consensus Bristol-Myers Squibb Company